You May Also Be Interested In:
Insulin enters the blood circulation and acts on the various organs and tissues to regulate glucose metabolism. Insulin binds to its specific cell surface receptors, activates a complex signal transduction pathway, and eventually leads to the opening of cell surface channels that take up glucose from the blood stream. The end result is the lowering of the blood glucose level.
Any blockade or efficiency decrease in this signaling pathway will result in compromised insulin action, affecting insulin's ability to regulate blood glucose. This is called insulin resistance. To compensate the decreased insulin sensitivity, human body produces more and more insulin. This leads to hyper-insulinia. The sustained high insulin level in the blood have detrimental effects on other metabolic processes, such as lipid metabolism and sex hormone metabolism. The broad category of human diseases resulting from insulin resistance is called X Syndrome and includes diabetes, high blood pressure, obesity, stroke, PCOS, etc.
Researches carried out in the last two decades at various laboratories have indicated that inositol molecules, particularly D-chiro-inositol and Myo-inositol, are important mediators for insulin action.
D-chiro-inositol was found to be present in the urine and blood of normal people but absent or at much reduced level in those of Type 2 diabetic patients, suggesting that Type 2 diabetic patients may not produce enough Inositol A and therefore exhibit a decrease in insulin sensitivity.
We discovered that buckwheat seeds contains large amount of inositol derivatives. We have further developed a proprietary technology that easily and cost-effectively converts the derivatives to active inositol compounds and subsequently isolates the active compounds as a pharmaceutical preparation, which we named "Newgenco TangZhiShu Capsule". The technology is appropriate for large-scale production. This technology was submitted out for patent application in China in 2001 and 2003, and granted in 2004 and 2005.
It was extracted from natural buckwheat seeds and contains a new kind of insulin sensitizera??D-Chiro-Inositol(DCI) &Myo-Inositol(MI) and demonstrated an excellent safety, efficacy profiles and dominant effect on patients with diabetes, hyperlipidemia, hypertension and obesity.
Description: Buckwheat extracts
Botanical resource: Fagopyrum esculentum Moench, Fagopyrum tatarium Moench
Characteristic: Brown powder, odorless, bitter in taste
(1) Total Chiro-inositol: 2000mg/100g
(2) Total flavone: 600mg/100g
Test Method: UV-Vis
Shelf life: 36month
Package: in bulk